Mev Dominguez-Valentin from The Department of Tumor Biology is the first author of the article “Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: A report from the Prospective Lynch Syndrome Database”, recently published in eClinicalMedicine, part of The Lancet Discovery Science. 

Åslaug Helland has been elected as a member of the prestigious Norwegian Academy of Science and Letters. Altogether, four new members are welcomed to the Academy’s Natural Sciences Division in 2023, and Åslaug Helland will join the Medical Sciences group. She will be formally presented with her diploma during a ceremony at the Academy of Science and Letters Annual Meeting, which will take place on Wednesday 3 May.
Commenting on her election, Åslaug Helland says: “I’m truly honored and grateful to be nominated and elected as a member of the prestigious Norwegian Academy of Science and Letters. I look forward to participating in and contributing to Academy activities”.

RADFORSK investment foundation has granted NOK 15 mill. for a new research and development project in targeted and personalized radiopharmacy, TARACAN - "TArgeted RAdionuclide Therapy (TRT) for CANcer". The project will take place at the Division of Cancer Medicine and Division of Radiology and Nuclear Medicine at Oslo University Hospital and will be led by Asta Juzeniene at the Institute for Cancer Research. In addition, the clinicians Øyvind Bruland and Mona Elisabeth Revheim will participate in the project. The project has gained attention through a report in the popular medical newspaper "Dagens Medisin".

The Colorectal Cancer Research Network is an international collaboration working towards an increased understanding of the mechanisms behind colorectal cancer, with the aim of improving treatment options. The Founders are connected to two of the leading Universities in the UK and the Institute for Cancer Genetics and Informatics at Oslo University hospital.
Håvard Danielsen and colleagues from the University of Oxford would like to invite you to a meeting about current practice, prediction and metastases for colon and rectal cancer, held in Oxford 30-31 March 2023.

Kushtrim Kryeziu is 37 years and defended his PhD at the Medical University of Vienna in 2016. Kryeziu was recruited to the Lothe lab in 2016 via an EU financed fellowship and was included in the Scientia Fellows postdoc program at the University of Oslo. His recruitment has proven highly beneficial for the development of the current project on functional oncology in advanced solid tumors. His competence in molecular cell biology and hands-on experience with anti-cancer drug development was instrumental to the development of our pre-clinical pharmacogenomics platform. Kryeziu has recently accepted a permanent position at the Institute for Cancer Research.